Key result
Hydroxychloroquine plus azithromycin linked to a ~28 ms QTc prolongation in SARS-CoV-2 patients.
Why the study?
Does Hydroxychloroquine/Azithromycin combination prolong the QT interval in adult patients with SARS-CoV-2 infection?
Population
84 adult patients with SARS-CoV-2 infection
Comparison
Hydroxychloroquine/Azithromycin combination
Authors
Loading...
Supports QTc monitoring with hydroxychloroquine/azithromycin in SARS-CoV-2; leaves open arrhythmia outcome impact in observational data.
Observational (n=84)
No
Does Hydroxychloroquine/Azithromycin combination prolong the QT interval in adult patients with SARS-CoV-2 infection?
Absolute Event Rate: 463% vs 435%
p-value: p=<0.001
Treatment with Hydroxychloroquine and Azithromycin in SARS-CoV-2 patients frequently leads to significant QTc prolongation, with acute renal failure being a strong predictor of extreme prolongation.
Chorin et al. (2020) conducted an observational in SARS-CoV-2 infection (n=84). Hydroxychloroquine and Azithromycin vs. Baseline (pre-treatment) was evaluated on Maximum QTc interval (ms) (p=<0.001). Treatment with Hydroxychloroquine and Azithromycin significantly prolonged the QTc interval from a baseline of 435 ms to a maximal value of 463 ms in patients with SARS-CoV-2 infection.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: